Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.

 

Understanding the Public Health Workforce’s COVID-19 Mental Health Challenges

The recently released Morbidity and Mortality Weekly Report (MMWR), Symptoms of Depression, Anxiety, Post-traumatic Stress Disorder and Suicidal Ideation Among State, Tribal, Local and Territorial Public Health Workers During the COVID-19 Pandemic, and the Public Health Workfo...

   Estimated Time: Well-Being, Workforce

Health Worker Burnout

On May 23, United States Surgeon General Dr. Vivek Murthy issued a new advisory, the Surgeon General’s Advisory Addressing Health Worker Burnout, highlighting the urgent need to address the health worker burnout crisis across the country. This advisory details recommendations ...

   Estimated Time: Well-Being, Workforce

​​COVID-19 Therapeutics Thr​esholds, Orders, and Replenishment by Jurisdiction

On April 25, 2022, the distribution process for COVID-19 therapeutics to state and territorial health departments transitioned from the previous allocation process to one that more closely aligns with the allocation and ordering process for vaccines. 

   Estimated Time: Administration, COVID-19, Economics

NIH Resource: Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications

Ritonavir, a strong cytochrome P450 (CYP) 3A4 inhibitor and a P-glycoprotein inhibitor, is coadministered with nirmatrelvir to increase the blood concentration of nirmatrelvir, thereby making it effective against SARS-CoV-2. Ritonavir may also increase blood concentrations of ...

   Estimated Time: Antivirals, COVID-19

FDA Updates Sotrovimab Emergency Use Authorization

The Centers for Disease Control and Prevention (CDC) Nowcast data from April 5, 2022,  estimates that the proportion of COVID-19 cases caused by the Omicron BA.2 variant is above 50% in all Health and Human Services (HHS) U.S. regions. Data included in the health care provider...

   Estimated Time: COVID-19, Pharmacology

New Paxlovid Dose Pack Author​ized by FDA

On April 14, 2022, the FDA revised the Emergency Use Authorization (EUA) for the COVID-19 oral antiviral therapeutic Paxlovid to authorize an additional dose pack presentation with appropriate dosing for patients with moderate renal impairment within the scope of the EUA. As a...

   Estimated Time: COVID-19, Pharmacology

NIH Resource: Study Looks for Long COVID Risk Factors 

In a study supported by the National Institute of Allergy and Infectious Diseases (NIAID), the National Center for Advancing Translational Sciences, and the National Institute on Drug Abuse, researchers enrolled 209 people ages 18 to 89 who had laboratory-confirmed SARS-CoV-2 ...

   Estimated Time: COVID-19, Epidemiology Outcomes

WHO resource: WHO updates its treatment guidelines to include molnupiravir

WHO has updated its living guidelines on COVID-19 therapeutics to include a conditional recommendation on molnupiravir, a new antiviral medicine. This is the first oral antiviral drug to be included in the treatment guidelines for COVID-19. As this is a new medicine, there ...

   Estimated Time: Antivirals, Coronavirus, COVID-19

Fact Sheet: COVID-19 Test to Treat

Through this program, people are able to get tested and – if they are positive and treatments are appropriate for them – receive a prescription from a health care provider, and have their prescription filled all at one location. These “One-Stop Test to Treat” sites are availab...

   Estimated Time: Antivirals, Coronavirus, COVID-19, Therapies

Palliative Care During the Pandemic (Podcast)

Top officials for the American Hospital Association and the Center to Advance Palliative Care (CAPC) convened virtually for a fireside chat to discuss the impact and importance of palliative care practices during the pandemic and share stories from experts in the field. 

   Estimated Time: Coronavirus, COVID-19, Supportive Care

FDA Resource: Fact Sheet for Healthcare Providers: Emergency Use Authorization for Bebtelovimab

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of bebtelovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at l...

   Estimated Time: Coronavirus, COVID-19, Therapies

Center to Advance Palliative Care: Online Clinical Training Courses For All Clinicians

All specialties and disciplines can strengthen their care of patients living with a serious illness. For CAPC members, CAPC’s online training curriculum provides free continuing education credits for physicians, nurses, social workers, and case managers at member organizations...

   Estimated Time: Coronavirus, COVID-19, Supportive Care

Center to Advance Palliative Care: COVID-19 Response Hub

Whether your organization is in the middle of a COVID-19 surge or planning forward, Center to Advance Palliative Care (CAPC) has tools, technical assistance, clinical training, and convening opportunities to help. 

   Estimated Time: Coronavirus, COVID-19, Supportive Care

Center to Advance Palliative Care: CAPC Toolkits

Drawn from best practices, CAPC toolkits are curated, proven resources for improving the care of people living with serious illness. Toolkits include technical assistance and tools for palliative care teams; serious illness strategies for health systems, health plans, and ACOs...

   Estimated Time: Coronavirus, COVID-19, Supportive Care

American Thoracic Society: Elevator Pitch: COVID-19 ARDS Subphenotypes (Podcast)

In this "Breathe Easy Elevator Pitch" podcast, Dr. Siva Bhavani interviews Dr. David Furfaro, and they discuss the study "Latent Class Analysis Reveals COVID-19-related ARDS Subgroups", recently published in the Blue Journal.

   Estimated Time: ARDS, Coronavirus, COVID-19

Prevalence of Select New Symptoms and Conditions Among Persons Aged Younger Than 20 Years and 20 Years or Older at 31 to 150 Days After Testing Positive or Negative for SARS-CoV-2

Understanding the frequency with which new symptoms and conditions emerge in the months following SARS-CoV-2 infection is important to inform patients’ expectations for recovery and allow health care professionals and health systems to address patients’ needs. Shortness of bre...

   Estimated Time: Coronavirus, COVID-19, Post COVID-19

Long-Term Cardiovascular Outcomes of COVID-19

The cardiovascular complications of acute coronavirus disease 2019 (COVID-19) are well described, but the post-acute cardiovascular manifestations of COVID-19 have not yet been comprehensively characterized. Here we used national healthcare databases from the US Department of ...

   Estimated Time: Coronavirus, COVID-19, Post COVID-19

PASC Dashboard: Post-Acute Sequelae of SARS-CoV-2 Infections (PASC) Estimates and Insights

The American Academy of Physical Medicine and Rehabilitation (AAPM&R) has undertaken comprehensive efforts to support our call for a national plan to address Post-Acute Sequelae of SARS-CoV-2 infection (PASC or Long COVID) and the millions Americans it is affecting. The PASC D...

   Estimated Time: Coronavirus, COVID-19, Post COVID-19, Statistics

Parallel Pandemics From the Mind of Medicine (Podcast)

This is a podcast series accounting for the parallel pandemics of COVID-19 and clinician burnout, while introducing the story of one undocumented patient who helped to reveal the authentic feelings and values of his healthcare team. With historically high mortality rates in th...

WHO Resource: WHO recommends two new drugs to treat COVID-19

WHO has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be. The first drug, baricitinib, is strongly recommended for pat...

   Estimated Time: Coronavirus, COVID-19